Pure Global AI
NCT06129188Not yet recruiting

Comparison of Procedural Sedation in TEE

Comparison of Remimazolam With Propofol for Procedural Sedation in TEE
University of Alabama at BirminghamPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Anesthesia
Drug/Device/Intervention
Remimazolam
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Alabama at Birmingham
Timeline & enrollment
Phase
Phase 1
Start date
Jan 01, 2024
End date
Jun 01, 2024
Enrollment
120 participants
Primary outcome

Blood pressure, physiologic parameter,Heart rate, physiologic parameter

Summary

The objective of this proposal is to conduct a prospective randomized study comparing the
 utility of sedating patients undergoing transesophageal echocardiographic studies with a
 novel, recently-FDA-approved sedative agent, remimazolam, versus the sedative used in our
 current practice at UAB, propofol. This study will investigate whether remimazolam offers any
 benefit over current care vis-à-vis hemodynamics or efficiency/throughput.
 
 This study will be conducted at the University of Alabama at Birmingham. All outpatients and
 inpatients scheduled for elective/non-emergent TEE in the UAB Heart and Vascular Center TEE
 lab will be considered for enrollment.

ICD-10 classifications
Anaesthetic, unspecifiedOther and unspecified general anaestheticsLocal anaestheticsOther complications of anaesthesiaComplication of anaesthesia during labour and delivery, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06129188
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06129188 through Pure Global AI's free database. This Phase 1 trial is sponsored by University of Alabama at Birmingham and is currently Not yet recruiting. The study focuses on Anesthesia. Target enrollment is 120 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.